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Background: An antimicrobial dressing containing ionic silver was found effective in reducing surgical-site
infection in a preliminary study of colorectal cancer elective surgery. We decided to test this finding in a
randomized, double-blind trial.
Methods: Adults undergoing elective colorectal cancer surgery at two university-affiliated hospitals were randomly
assigned to have the surgical incision dressed with AquacelW Ag Hydrofiber dressing or a common dressing. To
blind the patient and the nursing and medical staff to the nature of the dressing used, scrub nurses covered
AquacelW Ag Hydrofiber with a common wound dressing in the experimental arm, whereas a double common
dressing was applied to patients of control group. The primary end-point of the study was the occurrence of any
surgical-site infection within 30 days of surgery.
Results: A total of 112 patients (58 in the experimental arm and 54 in the control group) qualified for primary end-
point analysis. The characteristics of the patient population and their surgical procedures were similar. The overall
rate of surgical-site infection was lower in the experimental group (11.1% center 1, 17.5% center 2; overall 15.5%)
than in controls (14.3% center 1, 24.2% center 2, overall 20.4%), but the observed difference was not statistically
significant (P= 0.451), even with respect to surgical-site infection grade 1 (superficial) versus grades 2 and 3, or
grade 1 and 2 versus grade 3.
Conclusions: This randomized trial did not confirm a statistically significant superiority of AquacelW Ag Hydrofiber
dressing in reducing surgical-site infection after elective colorectal cancer surgery.
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Surgical-site infection (SSI) occurs in 300,000 to 500,000
patients who undergo surgery in the US each year. For sur-
gical patients, SSI are the most common hospital-acquired
infection. In clean-contaminated and contaminated surgery,
such as elective major colorectal surgery, there has been
wide discrepancy in the reported incidence of incisional
SSI, ranging from 3% to 30% [1,2], reflecting differences in
diagnostic criteria and follow-up applied. SSI is associated
with significant attributable morbidity and mortality, pro-
longed hospital length of stay, and a high cost to the patient
and the institution. Several studies have suggested a doub-
ling of the mortality rate, with an annual cost of $1.8 billion
to the US health care system and £1 billion to the National
Health Service in England [3,4]. Because the patient’s skin
is a major source of pathogens, it is conceivable that
improving skin antisepsis would decrease SSIs; a large ran-
domized trial has shown that preoperative cleansing of the
patient’s skin with chlorhexidine-alcohol is superior to
cleansing with povidone-iodine for preventing surgical-site
infection after clean-contaminated surgery, including colo-
rectal procedures [5].
Ionic silver (Ag+), which is the oxidized active state of
silver, has received renewed interest and research for use
as a prophylactic antimicrobial agent in wound dressings
due to its broad spectrum antibacterial range, including
aerobic, anaerobic, Gram-negative and Gram-positive
bacteria, as well as yeast and fungi [6-8]. AquacelW Ag
Hydrofiber dressing (ConvaTec, Princeton, NJ, USA) is a
moisture retention dressing that consists of soft non-
woven sodium carboxymethylcellulose fibers combined
with 1.2% ionic silver, which is distributed throughout the
dressing material. The concept of AquacelW Ag Hydrofiber
dressing is to retain the hydrofiber’s physical properties
with the additional benefits of ionic silver, which is slowly
released into the wound, creating a moist antimicrobial en-
vironment. Multiple clinical studies have been performed
to assess its effectiveness for the treatment of a variety of
wounds, managed in acute and chronic settings. Neverthe-
less, a recent Cochrane systematic review failed to find an
advantage for silver-containing wound dressings after ana-
lyzing 26 randomized controlled trials that compared
silver-containing wound dressings and topical agents with
silver-containing and non-silver-containing comparators
on uninfected wounds. The authors of the review con-
cluded that there is insufficient evidence to establish
whether silver-containing dressings or topical agents pro-
mote wound healing or prevent wound infection [9]. No
published randomized studies have previously examined
the effect of silver-containing wound dressing on the inci-
dence of SSI. The average baseline rate of SSI after colo-
rectal cancer elective surgery at the European Institute of
Oncology was 23% with common postoperative dressing; a
pilot prospective non-randomized study of 100 patientsshowed a reduction of this rate to 4% by substituting the
AquacelW Ag Hydrofiber dressing for the common dres-
sing [10]. We decided to test this preliminary finding in a
prospective, randomized, double-blind trial against a com-
mon dressing as control, having the main objective to
compare the efficacy of AquacelW Ag Hydrofiber dressing
with that of a common postoperative one for preventing
SSIs in colorectal cancer elective surgery.
Methods
Study design
We conducted this prospective, randomized trial between
June 2008 and September 2010 at two university-affiliated
hospitals in Italy (IEO, European Institute of Oncology,
Milano and University of Milano-Bicocca at San Gerardo
Hospital, Monza). The institutional review board and
Ethics Committee at each hospital approved the study
protocol, and written informed consent was obtained from
all patients before enrollment. The trial was initially regis-
tered at Central Registry of Randomized Clinical Trials of
the Italian Health Ministry, and then received registration
no. NCT00981110 by clinicaltrials.gov.
Patients
Patients aged 18 to 75 years who were undergoing colo-
rectal cancer elective surgery by laparotomic approach
were eligible for enrollment. Exclusion criteria were a
history of allergy to dressing components, evidence of
active infection at or adjacent to the operative site, coa-
gulopathy (defined as platelet count less than 50,000
cells/μL or a prothrombin time more than 18 seconds),
intestinal obstruction, active bowel bleeding, life expect-
ancy less than 6 months, inability to give written
informed consent or a program of minimally invasive
surgery (laparoscopy or robot- assisted).
Interventions
Enrolled patients were randomly assigned to have the
surgical incision dressed with Aquacel Ag Hydrofiber
dressing (ConvaTec) in the experimental arm, or a
common dressing (Mepore, Molnlycke Health Care,
Gothenburg, Sweden) in the control arm. To help match
the two groups and address potential inter-hospital differ-
ences, randomization was stratified by hospital with the
use of computer-generated randomization numbers
without blocking. In order to maintain the double-blind
characteristic of this trial, some actions were taken. First,
the generator of the assignment was a data manager, who
was separated from the executor; second, dressings were
applied by the scrub nurses in the operating theatre at the
end of each procedure. The Aquacel Ag Hydrofiber
dressing was covered by a common wound dressing in the
experimental arm, whereas a double common dressing
was applied to patients of the control group to blind the
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pendent data collector as to the nature of the dressing
used. All patients received a preoperative scrub and then
painting with an aqueous solution of 10% povidone-
iodine; all patients had mechanical bowel preparation and
antibiotic prophylaxis in agreement with predefined
protocols.
Efficacy outcomes
The primary end-point of the study was the occurrence
of any SSI within the 30 days after surgery. The operat-
ing surgeon became aware of which dressing had been
applied only after the superficial dressing was removed
on the seventh postoperative day. Similarly, both the
patients and the investigators who diagnosed SSI on the
basis of criteria developed by the Centers for Disease
Control and Prevention (CDC) remained unaware of the
group assignments until removal of the dressing. Sec-
ondary end-points included the occurrence of individual
types of SSIs. These were classified as superficial inci-
sional infection (which involved only the skin and sub-
cutaneous tissue and excluded stitch-related abscesses),
deep incisional infection (which involved fascia and
muscle), or organ-space infection (which involved any
organ or space other than the incised layer of body wall
that was opened or manipulated during the operation).
Clinical assessment
The surgical site and the patient’s vital signs were assessed
at least once a day during hospitalization, on discharge and
at the time of follow-up evaluation (30th postoperative
day). Dressings were removed on seventh postoperative day
as per protocol, or earlier whenever SSI was suspected.
Data from the assessment and follow-up of these patients
were entered into a software registry and analyzed by an
epidemiologist-biostatistician (DR). After discharge, the
investigators called the patients once a week during the 30-
day follow-up period and arranged for prompt clinical
evaluation if infection was suspected. Whenever SSI was
suspected or diagnosed, clinically relevant microbiologic
samples were cultured. Investigators, who were unaware of
the patients’ group assignments, assessed the seriousness of
all adverse events and determined whether they were
related to the study.
Statistical analysis
The average baseline rate of SSI at the participating hos-
pitals was 23% after colorectal cancer elective surgery
with standard postoperative dressing, and we estimated
that substituting the Aquacel Ag Hydrofiber dressing for
common would reduce this rate to 4%. This was the
overall SSI rate we detected in a pilot prospective non-
randomized study of 100 patients with colorectal cancer
who had elective surgery at the European Institute ofOncology in 2007 [10]. Therefore, we planned to enroll
56 patients in each study group for the study to have
80% power to detect a 19% difference in the rates of SSI
between the two groups, using a two-sided Fisher’s exact
test at a two-tailed significance level of P ≤0.05. The sig-
nificance of differences between the two study groups in
terms of patient characteristics was determined with the
use of the Wilcoxon rank-sum test for continuous vari-
ables in case of non-normally distributed data, unpaired
t-test otherwise. The center-effect on continuous variables
was tested using an analysis of variance (ANOVA) model
with center and treatment arm as the main effects without
interaction terms. Between-group comparisons for cat-
egorical variables were done using either the Fisher’s exact
test or the Cochran-Mantel-Haenszel Chi-square test
stratified by center as appropriate. Furthermore, between-
group comparisons for efficacy outcomes (for example,
the risk of any SSI) were done by estimating the univariate
(unadjusted) and multivariate (adjusted) odds-ratios in a
logistic regression analysis. Odds-ratios are tabulated
alongside their 95% confidence interval (CI).
The assessed risk factors were prespecified in the
protocol, and the statistical methods were preplanned.
All analyses were conducted using SAS 9.2 software
(Cary, NC, USA).
Results
Patients
A total population of 201 patients were screened for eli-
gibility during the 16-month accrual period of the study,
and 121 were randomly assigned to a study group: 62 to
the Aquacel Ag Hydrofiber dressing group and 59 to the
control dressing group. Nine patients dropped out of the
study after surgery (four in the Aquacel Ag Hydrofiber
and five in the control dressing group). Therefore, 112
patients (58 in the Aquacel Ag Hydrofiber dressing
group and 54 in the control dressing group) were
included in the analyses. A trial profile, conforming to
the Consolidated Standards of Reporting Trials guide-
lines, is shown in Figure 1.
The patients in the two study groups were similar with
respect to their demographic characteristics, type of
tumor (colon versus rectal), body mass index (BMI),
American Society of Anesthesiologists (ASA) score and
risk factors for infection (smoking status, preoperative
chemoradiation therapy). None of the considered variables
differed with respect to surgical center; only surgical
wound length differed, as the San Gerardo Monza Center
showed a significantly (P <0.0001 ANOVA F-test) longer
length (Tables 1 and 2). All patients received systemic
prophylactic antibiotics within the 30 minutes before the
initial incision, and there were no significant differences in
the type or number of antibiotics given to the two study
groups (data not shown).
Screened: 
201 
Eligible 
121 
Randomized
121 
Did not meet eligibility criteria (N°=62) 
Histology      4 
Age     15 
Active infections      1 
No preparation for surgery     9 
Stoma  derivation    14 
Renal failure      1 
Intestinal obstruction     9 
Blood transfusion      1 
Other       8 
Refused participation  18
Standard 
dressing 
59 
Aquacel®
Dressing 
62 
Analyzed 
for primary end point 
112 
Lost to follow-up                                        0
Drop out    9 
Aquacel ® Dressing    4 
Standard     5
Standard 
dressing 
54  
Aquacel®
Dressing 
58 
Screened 
201 
Eligible 
121 
Randomized
121 
Did not meet eligibility criteria (N°=62) 
Age     15 
Diverting stoma planned    14 
No preparation for surgery     9 
Intestinal obstruction     9 
Histology      4 
Active infections      1 
Renal failure      1 
Active bleeding      1 
Other       8 
Refused participation   18
Standard 
dressing 
59 
Aquacel® Ag
Dressing 
62 
Analyzed 
for primary end point 
112 
Lost to follow-up                                        0
Drop out    9 
Aquacel ® Ag Dressing   4 
Standard     5
Standard 
dressing 
54  
Aquacel® Ag
Dressing 
58 
Figure 1 Trial profile, conforming to the Consolidated Standards of Reporting Trials guidelines.
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Table 3 summarizes the main results. The overall rate of
SSI was lower in the experimental group, but the
observed difference was not statistically significant: there
were nine (15.5%) SSIs of any grade in the experimental
group and 11 (20.4%) in controls (P= 0.623). Infections
rates did not significantly differ with respect to surgical
center (experimental arm: 11.1% center 1, 17.5% center2, overall 15.5%; controls: 14.3% center 1, 24.2% center
2, overall 20.4% (data not shown), Cochran-Mantel-
Haenszel Stratified Test: P= 0.451).
There were no differences even with respect to SSI
grade 1 versus 2 and 3 or grade 1 and 2 versus 3
(Table 3). Use of Aquacel Ag Hydrofiber dressing was
not associated with significantly fewer superficial inci-
sional infections or deep infections. As expected, there
Table 1 Patients’ characteristics
Characteristic Arm N Mean ± SD Median Minimum and maximum Pa
Age (years) A 54 62.9 ± 9.0 64.0 35,76 0.593
B 58 63.6 ± 9.2 63.5 38,77
Overall 112 63.3 ± 9.0 64.0 35,77
Body mass index (kg/m2) A 54 25.4 ± 4.4 25.1 18,36 0.747
B 58 25.7 ± 4.3 24.9 19,39
Overall 112 25.5 ± 4.3 25.0 18,39
Wound length (cm) A 46 22.3 ± 7.2 20.0 14,44 0.154
B 48 19.9 ± 6.3 20.0 10,40
Overall 94 21.0 ± 6.8 20.0 10,44
aWilcoxon or unpaired t-test as appropriate. A: standard dressing; B: Aquacel Ag Hydrofiber dressing; SD: standard deviation.
Biffi et al. World Journal of Surgical Oncology 2012, 10:94 Page 5 of 9
http://www.wjso.com/content/10/1/94were no significant differences between the two study
groups in the incidence of organ-space infection (SSI
grade 3). Table 4 shows some characteristics of the
clinical assessment of the surgical wound, including
presence of necrosis, erythema, edema and hematoma;
none of these findings differed between groups, along
with detection of fever, shiver or leukocytosis.
Similarly, the need of an anticipated change of the
dressing was not significantly more frequent in the
control arm.
Table 5 reports univariate risk estimates of acquiring a
SSI in the study groups; only surgery for rectal cancer was
possibly significantly related to an increased risk of SSI
(unadjusted odds ratio: 2.68; 95% CI: 1.00 to 7.21;
P=0.051).This finding was also confirmed in the multi-
variate analysis (Table 6): adjusted odds ratio: 4.07; 95%
CI: 1.01 to 16.4; P= 0.048). Study arm, gender, surgical
center, smoking status, preoperative chemoradiationTable 2 Patients’ characteristics
Characteristic Aa
N (%)
Gender Female 25 (46.3)
Male 29 (53.7)
Diagnosis Colon 36 (66.7)
Rectal 18 (33.3)
Preoperative treatment CT+RT 7 (13.0)
None 47 (87.0)
Smoking status Never 29 (53.7)
Previous 18 (33.3)
Smoker 7 (13.0)
ASA I 4 (7.4)
II 40 (74.1)
III 10 (18.5)
aChi-square of Fisher’s exact test as appropriate; A: standard dressing; ASA: America
preoperative chemoradiation therapy.therapy, ASA score, age, BMI and surgical wound length
did not show any impact on SSI rate.Microbiology
Culture of the surgical site in infected patients yielded
growth of organisms (a total of 25 isolates), and similar
proportions of infected patients in the two study groups
(five of nine (55.5%) in the Aquacel Ag Hydrofiber group,
and six of eleven (54.5%) in the control dressing group)
had an identifiable microbiologic cause of infection.
Gram-positive aerobic bacteria (15 isolates) outnumbered
Gram-negative aerobic bacteria (10 isolates), and 20% of
cultures were polymicrobial.
There were no significant differences in the frequency
of isolating certain categories of organisms or particular
organisms in the experimental group as compared with
the control group.Bb Overall Pa
N (%)
22 (37.9) 47 (42.0) 0.444
36 (62.1) 65 (58.0)
41 (70.7) 77 (68.8) 0.687
17 (29.3) 17 (15.2)
7 (12.1) 14 (12.5) 1.000
51 (87.9) 98 (87.5)
28 (48.3) 57 (50.9)
20 (34.5) 38 (33.9) 0.759
10 (17.2) 17 (15.2)
3 (5.2) 7 (6.3)
46 (79.3) 86 (76.8) 0.787
9 (15.5) 19 (17.0)
n Society of Anesthesiologists score; B: Aquacel Ag Hydrofiber dressing; CT+RT:
Table 3 Primary outcome - surgical-site infections
Surgical-site
infection grade
A B Overall Pa
N (%) N (%)
None 43 (79.6) 49 (84.5) 92 (82.1)
1 8 (14.8) 5 (8.6) 13 (11.6) 0.802
2 2 (3.7) 3 (5.2) 5 (4.5)
3 1 (1.9) 1 (1.7) 2 (1.8)
None 43 (79.6) 49 (84.5) 92 (82.1) 0.623
Any 11 (20.4) 9 (15.5) 20 (17.9)
None 43 (79.6) 49 (84.5) 92 (82.1)
1 8 (14.8) 5 (8.6) 13 (11.6) 0.653
2,3 3 (5.6) 4 (6.9) 7 (6.3)
None 43 (79.6) 49 (84.5) 92 (82.1)
1,2 10 (18.5) 8 (13.8) 18 (16.1) 0.803
3 1 (1.9) 1 (1.7) 2 (1.8)
aChi-square or Fisher’s exact test as appropriate. A: standard dressing;
B: Aquacel Ag Hydrofiber dressing.
Table 4 Other outcomes
Characteristic A B Overall Pa
N (%) N (%)
Necrosis Fair 0 2 (3.5) 2 (1.8)
Light 1 (1.9) 0 1 (0.9) 0.361
None 53 (98.1) 56 (96.5) 109 (97.3)
Erythema Fair 2 (3.7) 0 2 (1.8)
Light 4 (7.4) 9 (15.5) 13 (11.6) 0.158
None 48 (88.9) 49 (84.5) 97 (86.6)
Edema Light 5 (9.3) 3 (5.2) 8 (7.1) 0.479
None 49 (90.7) 55 (94.8) 104 (92.9)
Hematoma No 51 (94.4) 53 (91.4) 104 (92.9) 0.718
Yes 3 (5.6) 5 (8.6) 8 (7.1)
Fever No 47 (87.0) 47 (81.0) 94 (83.9) 0.447
Yes 7 (13.0) 11 (19.0) 18 (16.1)
Shiver No 51 (94.4) 55 (94.8) 106 (94.6) 1.000
Yes 3 (5.6) 3 (5.2) 6 (5.4)
Leukocytosis No 45 (83.3) 48 (82.8) 93 (83.0) 1.000
Yes 9 (16.7) 10 (17.2) 19 (17.0)
Infection within
30 days
No 46 (85.2) 52 (89.7) 98 (87.5) 0.572
Yes 8 (14.8) 6 (10.3) 14 (12.5)
a
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Investigators who were unaware of the patients’ group
assignments assessed the seriousness of all adverse
events; none was determined to be related to the study.Chi-square of Fisher’s exact test as appropriate. A: standard dressing; ASA:
American Society of Anesthesiologists score; B: Aquacel Ag Hydrofiber
dressing.Discussion
Randomized studies have compared the efficacy of differ-
ent types [11-13] or doses [14,15] of systemic antibiotics
for preventing SSIs; influence of different preoperative
skin antisepsis agents was also investigated [5]. To our
knowledge, this is the first randomized controlled trial
addressing the efficacy of an ionic-silver-delivering
antimicrobial dressing in lowering the SSI rate of patients
having colorectal cancer elective open surgery.
Animal models have been used to study the perform-
ance and cytotoxicity of Aquacel Ag Hydrofiber dressing
in vivo. In a full-thickness infected mouse wound model,
Yates and colleagues showed that Aquacel Ag Hydrofiber
lowered wound bacteria loads, obtained superior wound
tensile strength, and accelerated epithelialization com-
pared with untreated infected wounds [16]. Multiple clin-
ical studies have been performed to assess Aquacel Ag
Hydrofiber effectiveness for the treatment of a variety of
acute and chronic wounds. Caruso et al. carried out a
stratified, randomized prospective, though un-blinded
study, comparing Aquacel Ag Hydrofiber and silver sulfa-
diazine in the management of partial thickness burns
[17,18]. Aquacel Ag Hydrofiber was associated with sig-
nificantly less pain and anxiety during dressing changes,
significantly fewer procedural and opiate medications, sig-
nificantly less burning and stinging during wear, and
greater cost-effectiveness than silver sulfadiazine.Other clinical studies on partial thickness burns treat-
ment showed good wound healing, reduced pain, fewer
dressing changes and better cost-effectiveness with
Aquacel Ag Hydrofiber compared to standard treatment
[19-21]. In patients with acute split-thickness skin-graft
donor sites and acute traumatic wounds [22,23], Aqua-
cel Ag Hydrofiber showed superior re-epithelialization
rates and was associated with less pain on dressing re-
moval in comparison with standard treatment. Jurczak
and colleagues of the Aquacel Ag Surgical/Trauma
Wound Study Group carried out a prospective, rando-
mized clinical trial comparing pain, comfort, exudate
management, wound healing and safety with Hydrofiber
dressing with ionic silver (Aquacel Ag Hydrofiber dres-
sing) and with povidone-iodine gauze for the treatment
of open surgical and traumatic wounds [22]. At final
evaluation, Aquacel Ag Hydrofiber dressing was signifi-
cantly better than povidone-iodine gauze for overall
ability to manage pain, overall comfort, wound trauma
on dressing removal, exudate handling and ease of use.
Rates of complete healing at study completion were
23% for Aquacel Ag Hydrofiber dressing and 9% for
povidone-iodine gauze (P-value was non-significant).
There are several limitations of our study that deserve
some mentions. First, results of this randomized trial are
conflicting with those initially reported by our group in
Table 5 Univariate risk estimates of acquiring a surgical-
site infection
Risk factor Unadjusted
odds ratio
95%
confidence
interval
P
Arm A Reference -
B 0.72 0.27,1.90 0.504
Gender Male Reference -
Female 0.40 0.13,1.18 0.097
Center European Institute of
Oncology
Reference -
San Gerardo Monza 0.57 0.19,1.70 0.313
Smoking
status
Never Reference -
Previous 1.42 0.50,4.09 0.598
Smoker 1.14 0.27,4.80 0.951
Diagnosis Colon Reference
Rectal 2.68 1.00,7.21 0.051
Preoperative
treatment
None Reference -
CT+RT 2.05 0.57,7.35 0.271
ASA I Reference -
II 1.27 0.14,11.3 0.998
III 1.60 0.15,17.4 0.658
Agea 1.02 0.96,1.08 0.564
Body mass
indexa
1.08 0.97,1.21 0.155
Wound lengtha 0.96 0.88,1.05 0.389
aOdds-ratio estimated by unit increase. A: standard dressing; B: Aquacel Ag
Hydrofiber dressing; CT+RT: preoperative chemoradiation therapy.
Table 6 Multivariate risk estimates of acquiring a
surgical-site infection
Risk factor Adjusted
odds ratio
95%
confidence
interval
P
Arm A Reference -
B 0.68 0.20,2.31 0.539
Gender Male Reference -
Female 0.86 0.22,3.36 0.828
Center European Institute
of Oncology
Reference -
San Gerardo
Monza
0.89 0.17,4.70 0.893
Smoking status Never Reference -
Previous 0.54 0.13,2.26 0.332
Active 1.35 0.19,9.74 0.539
Diagnosis Colon Reference
Rectal 4.07 1.01,16.4 0.048
Preoperative
treatment
None Reference -
CT+RT 1.96 0.26,14.9 0.516
ASA I Reference -
II 0.25 0.01,4.59 0.224
III 0.57 0.03,11.4 0.903
Agea 1.05 0.97,1.14 0.253
BMIa 1.08 0.93,1.24 0.317
Wound lengtha 0.96 0.84,1.09 0.535
aOdds-ratio estimated by unit increase. A: standard dressing; B: Aquacel Ag
Hydrofiber dressing; CT+RT: preoperative chemoradiation therapy.
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study carried out in 100 patients consecutively receiving
Aquacel Ag Hydrofiber dressing after elective colorectal
cancer surgery. In that report, we observed an overall
SSI rate of 4%, which is much less than the 15.5% we
detected in this randomized trial. However, limitations
of observational non-randomized studies are well known
and emphasized, especially uncertainty about whether all
confounders had been controlled for. Double-blinding
was accurately provided in this randomized trial, and we
can reasonably argue that initial results should be inter-
preted cautiously, particularly given the absence of blind-
ing in that initial experience. Moreover, the usage of the
secondary dressing to blind the study might have affected
the overall performance of the antimicrobial dressing.
Second, the overall rates of SSI of 17.9% in this study
are higher than those reported in some previous studies
[24,25]; nevertheless, they are similar to the pre-study
rates at the participating hospitals and those reported in
other studies [26] and are lower than the rates reported
in trials that used the CDC definition of infection andhad adequate follow-up [2,12,13], as we did in this trial.
In this study we universally enforced standard of care
preventive measures (for example, administering sys-
temic prophylactic antibiotics within the 30 minutes
before the first incision was made and, if needed,
clipping hair immediately before surgery) [27,28].
However, we did not use chlorhexidine-alcohol as the skin
preparation agent; although the povidone-iodine we used
possesses broad spectrum antimicrobial activity [27], a
recent randomized controlled trial demonstrated that pre-
operative cleansing of the patient’s skin with chlorhexidine-
alcohol is superior to cleansing with povidone-iodine for
preventing SSI after clean-contaminated surgery [5]. This is
probably related to its more rapid action, persistent activity
despite exposure to bodily fluids, and residual effect [29].
Finally, the sample size of this trial could appear smaller
than required, and the study globally underpowered to de-
tect a significant difference in infections rates, even
though the sample size was accurately determined on the
basis of a pilot non-randomized prospective study. We
were not able to enroll more patients in the timeframe we
assigned to the study, as minimally invasive surgery (a
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more and more applied to surgical treatment of colorectal
cancer. Superficial SSIs have been significantly reduced by
the application of minimally invasive techniques [30].
Precise robotic movements and fine manipulation of
tissues in a close and fixed operating field make especially
rectal cancer surgery an important application of minim-
ally invasive robotic surgery, and in fact robot-assisted
low-anterior resection was reported by ours and other
groups as a technically feasible and oncologically safe
procedure for treatment of rectal cancer [31,32].
Conclusion
In conclusion, Aquacel Ag Hydrofiber dressing showed a
reduction in the overall SSI rate compared with a
common postoperative dressing in elective colorectal
open major procedures, although the registered infec-
tions rates were not statistically significant. Moreover,
there were no significant differences between the two
study groups in the incidence of superficial and deep
infections of surgical wounds and, as expected, there
was no difference in organ-space infection rate either.
The finding that rectal cancer surgery is more prone to
SSI compared with colon surgery confirms previous
reports in the literature. No adverse events related to the
study were detected. More trials are needed to definitely
address this topic, testing new products developed
specifically for surgical incisions, such as Aquacel Ag
Surgical cover dressing (Hydrofiber Technology com-
bined with skin-friendly hydrocolloid substrate), which
provides a waterproof and viral and bacterial barrier that
allows for flexibility and extensibility during body
movement.
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